9/9/2011

An FDA advisory panel endorsed the approval of anticoagulant Xarelto to prevent stroke in patients with atrial fibrillation. Panel members said they wanted more alternatives to warfarin. Xarelto developers Johnson & Johnson and Bayer expect an FDA decision in November.

Related Summaries